New drug IASO-782 aims to tame immune attacks on blood cells

NCT ID NCT06534021

Recruiting now Disease control Sponsor: Shanghai IASO Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new drug called IASO-782 in 16 adults with autoimmune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA). These conditions cause the immune system to mistakenly attack blood cells. The study's main goal is to check the drug's safety and how well the body tolerates it. Participants receive a single dose of IASO-782 or a placebo, and researchers will monitor for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IASO-782 injection
What this could lead to: If successful, this could point toward a new treatment option for people with autoimmune blood disorders that haven't responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 16 participants, so safety and dosing are the main focus. It is too soon to know if IASO-782 will be effective, and there may be unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia, warm type autoimmune thrombocytopenia autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE THROMBOCYTOPENIA WARM AUTOIMMUNE HAEMOLYTIC ANAEMIA

Contacts and locations

Locations

Institute of Hematology, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.